Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Despite Pfizer management's cost-cutting and a large drug pipeline, revenue growth remains uncertain. Click here to read an ...

With volatility begetting opportunity, here are all six stocks I've bought through the first five months of 2025. Image ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

The stock is down by 56% since 2022 ... Here's what investors need to know. Pfizer's poor performance since 2022 is largely due to its coronavirus portfolio. After producing record revenue ...

Common use cases of AI in the supply chain illustrate the benefits for companies of integrating AI into their operations.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Shares of Pfizer Inc. PFE advanced 1.16% to $23.45 Thursday, on what proved to be an all-around great trading session for the ...

We recently published a list of Jim Cramer Recently Discussed These 15 Stocks. In this article, we are going to take a look ...

Pfizer’s stock has dropped 25% from its recent high, raising questions about whether it's a buy at $23. Pipeline failures and ...